valproic acid has been researched along with Encephalopathy, Toxic in 94 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 7.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| " Anticonvulsant effects were evaluated against seizures induced by 14 mg kg(-1) of 4-aminopyridine (4-AP) and by 110 mg kg(-1) of pentylenetetrazole (PTZ), and neurotoxicity by the rotarod test." | 7.72 | Is the interaction between felbamate and valproate against seizures induced by 4-aminopyridine and pentylenetetrazole in mice beneficial? ( Amat, G; Armijo, JA; Cuadrado, A, 2003) |
| " The aim of this study was to evaluate the profile of interactions between FBM and four conventional antiepileptic drugs (AEDs): clonazepam (CZP), ethosuximide (ESM), phenobarbital (PB), and valproate (VPA), in pentylenetetrazole (PTZ)-induced convulsions in mice, a model of myoclonic seizures in humans." | 7.72 | Isobolographic and subthreshold analysis of interactions among felbamate and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice. ( Borowicz, KK; Czuczwar, SJ; Luszczki, JJ, 2004) |
| "We present a case of a 29-year-old female with a history of epilepsy who was admitted for convulsive status epilepticus (CSE), which was controlled by intravenous VPA, as well as oral VPA and phenytoin." | 4.31 | Valproate-related hyperammonemic encephalopathy with generalized suppression EEG: a case report. ( Liu, X; Peng, X, 2023) |
| "Fetal exposure to the anticonvulsant drug valproic acid (VPA), used to treat certain types of epilepsy, increases the risk for birth defects, including neural tube defects, as well as learning difficulties and behavioral problems." | 4.02 | Folic acid supplementation rescues valproic acid-induced developmental neurotoxicity and behavioral alterations in zebrafish embryos. ( Bondesson, M; Garyfalidis, E; Gustafsson, JÅ; Kondamadugu, VS; Muhsen, M; Riu, A; Youngs, J, 2021) |
| "A novel class of 19 carbamates was synthesized, and their anticonvulsant activity was comparatively evaluated in the rat maximal electroshock (MES) and subcutaneous metrazol (scMet) seizure tests and pilocarpine-induced status epilepticus (SE) model." | 3.78 | Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. ( Bialer, M; Hen, N; Yagen, B, 2012) |
| "The use of lithium carbonate for the treatment of mood disorders in old age has decreased at a dramatic rate in favor of valproate." | 3.73 | Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. ( Anderson, G; Bronskill, S; Gill, S; Mamdani, M; Rochon, P; Shulman, KI; Sykora, K; Wodchis, WP, 2005) |
| "Isobolographic analysis was used to characterize the interactions between stiripentol (STP) and clonazepam (CZP), ethosuximide (ETS), phenobarbital (PB), and valproate (VPA) in suppressing pentylenetetrazole (PTZ)-induced clonic seizures in mice." | 3.73 | Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis. ( Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 3.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| " Anticonvulsant effects were evaluated against seizures induced by 14 mg kg(-1) of 4-aminopyridine (4-AP) and by 110 mg kg(-1) of pentylenetetrazole (PTZ), and neurotoxicity by the rotarod test." | 3.72 | Is the interaction between felbamate and valproate against seizures induced by 4-aminopyridine and pentylenetetrazole in mice beneficial? ( Amat, G; Armijo, JA; Cuadrado, A, 2003) |
| " The aim of this study was to evaluate the profile of interactions between FBM and four conventional antiepileptic drugs (AEDs): clonazepam (CZP), ethosuximide (ESM), phenobarbital (PB), and valproate (VPA), in pentylenetetrazole (PTZ)-induced convulsions in mice, a model of myoclonic seizures in humans." | 3.72 | Isobolographic and subthreshold analysis of interactions among felbamate and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice. ( Borowicz, KK; Czuczwar, SJ; Luszczki, JJ, 2004) |
| "Valproic acid (VPA) is a broad-spectrum, antiepileptic drug, and it is also a potent teratogen." | 2.72 | Emerging mechanisms of valproic acid-induced neurotoxic events in autism and its implications for pharmacological treatment. ( Fukunaga, K; Han, F; Lin, W; Meng, F; Naveed, M; Taleb, A; Xu, X; Zhang, G; Zhou, QG, 2021) |
| "VPA is widely used for the treatment of generalized epilepsy." | 2.61 | [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy]. ( Araki, M; Mukai, T; Naka, H; Shishido, T; Tokinobu, H; Yamada, H, 2019) |
| "Valproic acid (VPA) is a drug mainly used to treat epilepsy." | 2.55 | [Treatment of encephalopathy by means of valproic acid with carglumic acid: two case reports and a review of the literature]. ( Ceberio-Hualde, L; Cebrian-Novella, D; Diaz Alvarez-Mediavilla, J; Gomez-Del Olmo, V; Nava-Mateos, JJ; Roiz-Rey, P, 2017) |
| "Carnitine is an essential cofactor in the proper metabolism of valproic acid and ammonia elimination." | 2.48 | Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. ( Mock, CM; Schwetschenau, KH, 2012) |
| "Carnitine is an amino acid derivative that is an essential cofactor in the beta-oxidation of fatty acids." | 2.45 | Carnitine in the treatment of valproic acid-induced toxicity. ( Hantson, P; Lheureux, PE, 2009) |
| "The patient developed hyperammonaemic encephalopathy due to sodium valproate overdose and was treated with supportive care and renal replacement therapy." | 1.91 | Valproate overdose leading to hyperammonaemic encephalopathy. ( Gupta, S; Sharma, DS; Sharma, P, 2023) |
| "This is a type of VPA-related encephalopathy, different from dose-dependent toxic encephalopathy, hyperammonaemic encephalopathy or encephalopathy related to liver failure." | 1.91 | Cerebral and cerebellar pseudoatrophy associated with valproic acid. Report of three pediatric cases. ( Arias-Vivas, E; Duat-Rodríguez, A; García-Peñas, JJ; González-Alguacil, E; Gutiérrez-Delicado, E; Heppe-Montero, M; Justel-Rodríguez, M; Ordoño-Saiz, MV; Púa-Torrejón, RC; Ruiz-Falcó-Rojas, ML; Soto-Insuga, V, 2023) |
| " Perturbations of these endpoints are described as common key events in adverse outcome pathways (AOPs) specific for DNT." | 1.62 | Combining in vitro assays and mathematical modelling to study developmental neurotoxicity induced by chemical mixtures. ( Bal-Price, A; Bopp, SK; Carpi, D; Mendoza-de Gyves, E; Paini, A; Pistollato, F; Worth, A, 2021) |
| "Melatonin is an antioxidant and scavenger of free radicals secreted by the pineal gland." | 1.48 | Valproic Acid Induced Neurotoxicological Manifestations and its Mitigation by Melatonin in Rat Brain Synaptosomes. ( Chaudhary, S; Parvez, S, 2018) |
| "VPA-induced encephalopathy is an uncommon but serious adverse effect that should be considered in patients with cognitive decline during VPA treatment." | 1.42 | [Valproate can induce reversible encephalopathy]. ( Christensen, J; Harbo, T; Prakash, S, 2015) |
| "Treatment with rosiglitazone (5, 10 mg/kg) and VPA (100, 200 mg/kg) for 21 days significantly attenuated these behavioral, biochemical, and cellular alterations as compared to control (QA 200 nmol) group." | 1.40 | Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways. ( Chaudhary, T; Kumar, A; Mishra, J, 2014) |
| "EEG was suggestive of hypsarrhythmia." | 1.40 | Encephalopathy in an infant with infantile spasms: possible role of valproate toxicity. ( Sampath, S; Sivathanu, S; Sunderkumar, S; Veerasamy, M, 2014) |
| "VPA-induced encephalopathy is an uncommon but serious adverse effect that should be considered in patients with cognitive decline during VPA treatment." | 1.40 | [Valproate can induce reversible encephalopathy]. ( Christensen, J; Harbo, T; Prakash, S, 2014) |
| " This case report indicates that even non-chronic MDMA use may cause subacute toxic encephalopathy in which the clinical evolution is paralleled by neuroimaging changes in specific cerebral areas." | 1.35 | Hippocampal remodelling after MDMA neurotoxicity: a single case study. ( Amistà, P; Battaglia, M; Bertagnoni, GE; Carollo, C; Costanzo, R; Lupi, A; Martinuzzi, A; Nifosì, F; Perini, G; Toffanin, T; Vestri, A, 2009) |
| "Valproic acid (VPA) has been used for many years as a drug of choice for epilepsy and mood disorders." | 1.35 | Chronic dietary administration of valproic acid protects neurons of the rat nucleus basalis magnocellularis from ibotenic acid neurotoxicity. ( Brignani, S; Contestabile, A; Eleuteri, S; Monti, B, 2009) |
| "The aim of this study was to determine and compare the anticonvulsant and acute adverse (neurotoxic) effects of imperatorin and osthole (two natural coumarin derivatives) with valproate (a classical antiepileptic drug) in the maximal electroshock seizure and chimney tests in mice." | 1.35 | Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. ( Andres-Mach, M; Cisowski, W; Czuczwar, SJ; Glensk, M; Glowniak, K; Luszczki, JJ; Wojda, E, 2009) |
| "The declaration of brain death requires a standardized clinical neurologic examination and, importantly, the resolution of the underlying cause." | 1.35 | Valproic acid intoxication imitating brain death. ( Auinger, K; Maggiorini, M; Müller, V; Rudiger, A, 2009) |
| " The supplier group was much more sensitive to these toxic effects." | 1.34 | Valproate-induced developmental neurotoxicity is affected by maternal conditions including shipping stress and environmental change during early pregnancy. ( Hori, Y; Kuwagata, M; Ogawa, T; Shioda, S, 2007) |
| "Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated." | 1.33 | Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children. ( Augspach-Hofmann, R; Bendl, C; Buesing, D; Fitzek, S; Gerstner, T; Goetze, G; Haensch, CA; Klostermann, W; Koenig, SA; Lippert, G; Longin, E; Macke, A; Mayer, G; Reuland, M; Scheid, B; Wenzel, D, 2006) |
| "Valproic acid induced coma was likely related to a urea cycle enzymopathy." | 1.32 | Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report. ( Elgudin, L; Hall, Y; Schubert, D, 2003) |
| "Valproic acid (VPA) has long been used as an antiepileptic drug and recently as a mood stabilizer, and evidence is increasing that VPA exerts neuroprotective effects through changes in a variety of intracellular signalling pathways including upregulation of Bcl-2 protein with an antiapoptotic property and inhibiting glycogen synthase kinase 3-beta, which is considered to promote cell survival." | 1.32 | Benefit of valproic acid in suppressing disease progression of ALS model mice. ( Goto, M; Hamasaki, T; Miyaguchi, K; Sakoda, S; Sugai, F; Sumi, H; Yamamoto, Y; Zhou, Z, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 41 (43.62) | 29.6817 |
| 2010's | 40 (42.55) | 24.3611 |
| 2020's | 13 (13.83) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, ZF | 1 |
| Chai, KY | 1 |
| Piao, HR | 1 |
| Kwak, KC | 1 |
| Quan, ZS | 1 |
| Hen, N | 1 |
| Bialer, M | 1 |
| Yagen, B | 1 |
| Ojiro, R | 1 |
| Watanabe, Y | 1 |
| Okano, H | 1 |
| Takahashi, Y | 1 |
| Takashima, K | 1 |
| Tang, Q | 1 |
| Ozawa, S | 1 |
| Saito, F | 1 |
| Akahori, Y | 1 |
| Jin, M | 1 |
| Yoshida, T | 1 |
| Shibutani, M | 1 |
| Anthonipillai, P | 1 |
| Sharp, G | 1 |
| Kimber, J | 1 |
| Ziauddin, V | 1 |
| Chetwood, JD | 1 |
| Koorey, D | 1 |
| Bryant, C | 1 |
| Ishida, K | 1 |
| Tatsumi, K | 1 |
| Minamigawa, Y | 1 |
| Mori, K | 1 |
| Matsumaru, D | 1 |
| Nagase, H | 1 |
| Kanda, Y | 1 |
| Takuma, K | 1 |
| Nakanishi, T | 1 |
| Liu, X | 1 |
| Peng, X | 1 |
| Sharma, DS | 1 |
| Gupta, S | 1 |
| Sharma, P | 1 |
| Ordoño-Saiz, MV | 1 |
| Púa-Torrejón, RC | 1 |
| Justel-Rodríguez, M | 1 |
| Arias-Vivas, E | 1 |
| Heppe-Montero, M | 1 |
| González-Alguacil, E | 1 |
| Duat-Rodríguez, A | 1 |
| Ruiz-Falcó-Rojas, ML | 1 |
| García-Peñas, JJ | 1 |
| Gutiérrez-Delicado, E | 1 |
| Soto-Insuga, V | 1 |
| Khakwani, A | 1 |
| Gannon, D | 1 |
| Hsu, SW | 1 |
| Hsu, PC | 1 |
| Chang, WS | 1 |
| Yu, CC | 1 |
| Wang, YC | 1 |
| Yang, JS | 1 |
| Tsai, FJ | 1 |
| Chen, KY | 1 |
| Tsai, CW | 1 |
| Bau, DT | 1 |
| Chaudhary, S | 2 |
| Sahu, U | 1 |
| Parvez, S | 2 |
| Taleb, A | 1 |
| Lin, W | 1 |
| Xu, X | 1 |
| Zhang, G | 1 |
| Zhou, QG | 1 |
| Naveed, M | 1 |
| Meng, F | 1 |
| Fukunaga, K | 1 |
| Han, F | 1 |
| Muhsen, M | 1 |
| Youngs, J | 1 |
| Riu, A | 1 |
| Gustafsson, JÅ | 1 |
| Kondamadugu, VS | 1 |
| Garyfalidis, E | 1 |
| Bondesson, M | 1 |
| Pistollato, F | 1 |
| Carpi, D | 1 |
| Mendoza-de Gyves, E | 1 |
| Paini, A | 1 |
| Bopp, SK | 1 |
| Worth, A | 1 |
| Bal-Price, A | 1 |
| Nava-Mateos, JJ | 1 |
| Roiz-Rey, P | 1 |
| Diaz Alvarez-Mediavilla, J | 1 |
| Cebrian-Novella, D | 1 |
| Gomez-Del Olmo, V | 1 |
| Ceberio-Hualde, L | 1 |
| Attoff, K | 1 |
| Gliga, A | 1 |
| Lundqvist, J | 1 |
| Norinder, U | 1 |
| Forsby, A | 1 |
| Triplett, KE | 1 |
| Murray, R | 1 |
| Anstey, M | 1 |
| Izadi Firouzabadi, L | 1 |
| Geer, K | 1 |
| Mead, P | 1 |
| Yamada, H | 1 |
| Shishido, T | 1 |
| Mukai, T | 1 |
| Araki, M | 1 |
| Naka, H | 1 |
| Tokinobu, H | 1 |
| Viloria Alebesque, A | 1 |
| Montes Castro, N | 1 |
| Arcos Sánchez, C | 1 |
| Vicente Gordo, D | 1 |
| Kazim, S | 1 |
| Mohindra, R | 1 |
| Gosselin, S | 1 |
| Larocque, A | 1 |
| Ray, S | 2 |
| Skellett, S | 2 |
| Stern, M | 1 |
| Gierse, A | 1 |
| Tan, S | 1 |
| Bicker, G | 1 |
| Vishnu, VY | 1 |
| Kesav, P | 1 |
| Goyal, MK | 1 |
| Modi, M | 1 |
| Prabhakar, S | 1 |
| Rigamonti, A | 1 |
| Lauria, G | 1 |
| Grimod, G | 1 |
| Bianchi, G | 1 |
| Salmaggi, A | 1 |
| Fernández Colomer, B | 1 |
| Rekarte García, S | 1 |
| García López, JE | 1 |
| Pérez González, C | 1 |
| Montes Granda, M | 1 |
| Coto Cotallo, GD | 1 |
| Mishra, J | 1 |
| Chaudhary, T | 1 |
| Kumar, A | 1 |
| Selvi, Y | 1 |
| Annagur, BB | 1 |
| Sayin, AA | 1 |
| Akbaba, N | 1 |
| Pegg, EJ | 1 |
| Zaman, F | 1 |
| Sivathanu, S | 1 |
| Sampath, S | 1 |
| Veerasamy, M | 1 |
| Sunderkumar, S | 1 |
| Smirnova, L | 1 |
| Block, K | 1 |
| Sittka, A | 1 |
| Oelgeschläger, M | 1 |
| Seiler, AE | 1 |
| Luch, A | 1 |
| Rybka, S | 1 |
| Obniska, J | 1 |
| Rapacz, A | 1 |
| Filipek, B | 1 |
| Kamiński, K | 1 |
| Sundin, JR | 1 |
| Øksengård, AR | 1 |
| Røste, LS | 1 |
| Svendsen, J | 1 |
| Ihle-Hansen, H | 1 |
| Kowalski, PC | 1 |
| Dowben, JS | 1 |
| Keltner, NL | 1 |
| Prakash, S | 2 |
| Harbo, T | 2 |
| Christensen, J | 2 |
| Laliberté, V | 1 |
| Yu, C | 1 |
| Rej, S | 1 |
| Fan, CC | 1 |
| Huang, MC | 1 |
| Liu, HC | 1 |
| Nifosì, F | 1 |
| Martinuzzi, A | 1 |
| Toffanin, T | 1 |
| Costanzo, R | 1 |
| Vestri, A | 1 |
| Battaglia, M | 1 |
| Bertagnoni, GE | 1 |
| Lupi, A | 1 |
| Amistà, P | 1 |
| Carollo, C | 1 |
| Perini, G | 1 |
| Mehndiratta, MM | 1 |
| Mehndiratta, P | 1 |
| Phul, P | 1 |
| Garg, S | 1 |
| Lheureux, PE | 1 |
| Hantson, P | 1 |
| Abreu, LN | 1 |
| Issler, C | 1 |
| Lafer, B | 1 |
| Eleuteri, S | 1 |
| Monti, B | 1 |
| Brignani, S | 1 |
| Contestabile, A | 1 |
| Luszczki, JJ | 4 |
| Wojda, E | 1 |
| Andres-Mach, M | 1 |
| Cisowski, W | 1 |
| Glensk, M | 1 |
| Glowniak, K | 1 |
| Czuczwar, SJ | 4 |
| Kuwagata, M | 2 |
| Ogawa, T | 2 |
| Shioda, S | 2 |
| Nagata, T | 1 |
| Hogberg, HT | 1 |
| Kinsner-Ovaskainen, A | 1 |
| Coecke, S | 1 |
| Hartung, T | 1 |
| Bal-Price, AK | 1 |
| Auinger, K | 1 |
| Müller, V | 1 |
| Rudiger, A | 1 |
| Maggiorini, M | 1 |
| Granel, B | 1 |
| Gavaret, M | 1 |
| Le Baut, X | 1 |
| Sautereau, N | 1 |
| Rodriguez, D | 1 |
| Rossi, P | 1 |
| Bagnères, D | 1 |
| Demoux, AL | 1 |
| Francès, Y | 1 |
| Young, L | 1 |
| Coffey, BJ | 1 |
| Mesquita, J | 1 |
| Cepa, S | 1 |
| Silva, L | 1 |
| Machado, A | 1 |
| Scarano, V | 1 |
| Bellarosa, I | 1 |
| Bertogliatti, S | 1 |
| Terracciano, AM | 1 |
| Orlando, V | 1 |
| Gomez-Ibañez, A | 1 |
| Urrestarazu-Bolumburu, E | 1 |
| Viteri-Torres, C | 1 |
| Prins, MC | 1 |
| van Meijel, JJ | 1 |
| Garg, R | 1 |
| Sunder, RA | 1 |
| Mock, CM | 1 |
| Schwetschenau, KH | 1 |
| Bocchetta, A | 1 |
| Siddu, A | 1 |
| Sardu, C | 1 |
| Sarnicola, A | 1 |
| Martinelli, V | 1 |
| Grynnerup, A | 1 |
| Fernández, IS | 1 |
| Hernández, JC | 1 |
| Martínez, AD | 1 |
| López, JM | 1 |
| García-Alix, A | 1 |
| Lewis, C | 1 |
| Deshpande, A | 1 |
| Tesar, GE | 1 |
| Dale, R | 1 |
| Krug, AK | 1 |
| Kolde, R | 1 |
| Gaspar, JA | 1 |
| Rempel, E | 1 |
| Balmer, NV | 1 |
| Meganathan, K | 1 |
| Vojnits, K | 1 |
| Baquié, M | 1 |
| Waldmann, T | 1 |
| Ensenat-Waser, R | 1 |
| Jagtap, S | 1 |
| Evans, RM | 1 |
| Julien, S | 1 |
| Peterson, H | 1 |
| Zagoura, D | 1 |
| Kadereit, S | 1 |
| Gerhard, D | 1 |
| Sotiriadou, I | 1 |
| Heke, M | 1 |
| Natarajan, K | 1 |
| Henry, M | 1 |
| Winkler, J | 1 |
| Marchan, R | 1 |
| Stoppini, L | 1 |
| Bosgra, S | 1 |
| Westerhout, J | 1 |
| Verwei, M | 1 |
| Vilo, J | 1 |
| Kortenkamp, A | 1 |
| Hescheler, J | 1 |
| Hothorn, L | 1 |
| Bremer, S | 1 |
| van Thriel, C | 1 |
| Krause, KH | 1 |
| Hengstler, JG | 1 |
| Rahnenführer, J | 1 |
| Leist, M | 1 |
| Sachinidis, A | 1 |
| Cheng, M | 1 |
| Tang, X | 1 |
| Wen, S | 1 |
| Yue, J | 1 |
| Wang, H | 1 |
| Sobaniec-Lotowska, ME | 1 |
| Ubogu, EE | 1 |
| Sagar, SM | 1 |
| Lerner, AJ | 1 |
| Maddux, BN | 1 |
| Suarez, JI | 1 |
| Werz, MA | 1 |
| Angehagen, M | 1 |
| Ben-Menachem, E | 1 |
| Rönnbäck, L | 1 |
| Hansson, E | 1 |
| Cuadrado, A | 1 |
| Amat, G | 1 |
| Armijo, JA | 1 |
| Elgudin, L | 1 |
| Hall, Y | 1 |
| Schubert, D | 1 |
| Latour, P | 1 |
| Biraben, A | 1 |
| Polard, E | 1 |
| Bentué-Ferrer, D | 1 |
| Beauplet, A | 1 |
| Tribut, O | 1 |
| Allain, H | 1 |
| Yehya, N | 1 |
| Saldarini, CT | 1 |
| Koski, ME | 1 |
| Davanzo, P | 1 |
| Borowicz, KK | 1 |
| Nakazato, Y | 1 |
| Ando, S | 1 |
| Yamamoto, T | 1 |
| Tamura, N | 1 |
| Shimazu, K | 1 |
| Sugai, F | 1 |
| Yamamoto, Y | 1 |
| Miyaguchi, K | 1 |
| Zhou, Z | 1 |
| Sumi, H | 1 |
| Hamasaki, T | 1 |
| Goto, M | 1 |
| Sakoda, S | 1 |
| Peng, GS | 1 |
| Li, G | 1 |
| Tzeng, NS | 1 |
| Chen, PS | 1 |
| Chuang, DM | 1 |
| Hsu, YD | 1 |
| Yang, S | 1 |
| Hong, JS | 1 |
| Mayerhoff, DI | 1 |
| Nurenberg, J | 1 |
| Shah, S | 1 |
| Schleifer, SJ | 1 |
| Shulman, KI | 1 |
| Sykora, K | 1 |
| Gill, S | 1 |
| Mamdani, M | 1 |
| Bronskill, S | 1 |
| Wodchis, WP | 1 |
| Anderson, G | 1 |
| Rochon, P | 1 |
| Panda, S | 1 |
| Radhakrishnan, K | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Thygesen, KS | 1 |
| Wolf, P | 1 |
| Sobaniec-Łotowska, ME | 1 |
| Lotowska, JM | 1 |
| Gerstner, T | 1 |
| Buesing, D | 1 |
| Longin, E | 1 |
| Bendl, C | 1 |
| Wenzel, D | 1 |
| Scheid, B | 1 |
| Goetze, G | 1 |
| Macke, A | 1 |
| Lippert, G | 1 |
| Klostermann, W | 1 |
| Mayer, G | 1 |
| Augspach-Hofmann, R | 1 |
| Fitzek, S | 1 |
| Haensch, CA | 1 |
| Reuland, M | 1 |
| Koenig, SA | 1 |
| Embacher, N | 1 |
| Karner, E | 1 |
| Wanschitz, J | 1 |
| Beer, R | 1 |
| Trinka, E | 1 |
| Ratnaraj, N | 1 |
| Patsalos, PN | 1 |
| Beyenburg, S | 1 |
| Back, C | 1 |
| Diederich, N | 1 |
| Lewis, M | 1 |
| Reuber, M | 1 |
| Levisohn, PM | 1 |
| Holland, KD | 1 |
| Hori, Y | 1 |
| Dealberto, MJ | 1 |
| Habermeyer, B | 1 |
| Hess, M | 1 |
| Kozomara-Hocke, P | 1 |
| Mager, R | 1 |
| Kawohl, W | 1 |
| Parize, P | 1 |
| Beuret, P | 1 |
| Fischer, C | 1 |
| Fernández, EA | 1 |
| González, CG | 1 |
| Pardillo, JC | 1 |
| García, VM | 1 |
| Stewart, JT | 1 |
| Solomon, GE | 1 |
| Alao, AO | 1 |
| Dewan, MJ | 1 |
| Sbei, M | 1 |
| Campellone, JV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study[NCT05881928] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-07-25 | Not yet recruiting | ||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for valproic acid and Encephalopathy, Toxic
| Article | Year |
|---|---|
L-carnitine supplementation as a potential therapy for suspected hyperammonaemic encephalopathy.
Topics: Adult; Anticonvulsants; Blood Chemical Analysis; Carnitine; Cerebral Palsy; Dietary Supplements; Epi | 2019 |
Emerging mechanisms of valproic acid-induced neurotoxic events in autism and its implications for pharmacological treatment.
Topics: Animals; Anticonvulsants; Autism Spectrum Disorder; Female; Humans; Neurotoxicity Syndromes; Pregnan | 2021 |
[Treatment of encephalopathy by means of valproic acid with carglumic acid: two case reports and a review of the literature].
Topics: Aged; Anticonvulsants; Female; Glutamates; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Valpr | 2017 |
[Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Topics: Aged; Ammonia; Anticonvulsants; Biomarkers; Cardiomyopathies; Carnitine; Consciousness Disorders; Ep | 2019 |
Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Diagnosis, Differential; Humans; Hyperammonemia; Male; Neur | 2014 |
Carnitine in the treatment of valproic acid-induced toxicity.
Topics: Animals; Anticonvulsants; Antidotes; Carnitine; Chemical and Drug Induced Liver Injury; Energy Metab | 2009 |
Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
Topics: Carnitine; Humans; Hyperammonemia; Neurotoxicity Syndromes; Valproic Acid | 2012 |
Valproate-induced hyperammonemic encephalopathy: a brief review.
Topics: Adult; Anticonvulsants; Child; Hepatic Encephalopathy; Humans; Hyperammonemia; Models, Biological; N | 2012 |
Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting.
Topics: Antimanic Agents; Hospitals, Psychiatric; Humans; Hyperammonemia; Neurotoxicity Syndromes; Valproic | 2007 |
1 trial available for valproic acid and Encephalopathy, Toxic
| Article | Year |
|---|---|
Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Double-Blind Method; Female; Fructose; Humans; Magn | 2007 |
84 other studies available for valproic acid and Encephalopathy, Toxic
| Article | Year |
|---|---|
Synthesis and anticonvulsant activity of 7-alkoxyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Mice; Neurotoxicity Syndromes; Quinolines; Seizure | 2005 |
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
Topics: Animals; Anticonvulsants; Carbamates; Male; Mice; Neurotoxicity Syndromes; Rats; Rats, Sprague-Dawle | 2012 |
Gene expression profiles of multiple brain regions in rats differ between developmental and postpubertal exposure to valproic acid.
Topics: Animals; Brain; Hippocampus; Male; Neurogenesis; Neurotoxicity Syndromes; Prenatal Exposure Delayed | 2022 |
Valproate-Associated Hyperammonaemic Encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Neurotoxicity Syndromes; | 2022 |
Hyperammonaemic encephalopathy.
Topics: Brain Diseases; Humans; Neurotoxicity Syndromes; Valproic Acid | 2022 |
Neuronal differentiation reporter mice as a new methodology for detecting in vivo developmental neurotoxicity.
Topics: Animals; Cell Line; Female; Mammals; Mice; Neurons; Neurotoxicity Syndromes; Pregnancy; Rats; Valpro | 2022 |
Valproate-related hyperammonemic encephalopathy with generalized suppression EEG: a case report.
Topics: Adult; Anticonvulsants; Brain Diseases; Electroencephalography; Epilepsy; Female; Humans; Hyperammon | 2023 |
Valproate overdose leading to hyperammonaemic encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Male; Neurotoxicity Syndromes; Valproic Aci | 2023 |
Cerebral and cerebellar pseudoatrophy associated with valproic acid. Report of three pediatric cases.
Topics: Anticonvulsants; Brain; Brain Diseases; Cerebellum; Child; Child, Preschool; Epilepsy; Humans; Neuro | 2023 |
Protective effects of valproic acid on 6-hydroxydopamine-induced neuroinjury.
Topics: Animals; Apoptosis; Caspase 3; Cell Death; Cell Line, Tumor; Cell Survival; Dopamine; Humans; Mice; | 2020 |
Melatonin attenuates branch chain fatty acid induced apoptosis mediated neurodegeneration.
Topics: Animals; Antioxidants; Apoptosis; Behavior, Animal; Cell Line, Tumor; Cell Survival; Cerebellum; Cer | 2021 |
Folic acid supplementation rescues valproic acid-induced developmental neurotoxicity and behavioral alterations in zebrafish embryos.
Topics: Animals; Animals, Genetically Modified; Anticonvulsants; Behavior, Animal; Dietary Supplements; Embr | 2021 |
Combining in vitro assays and mathematical modelling to study developmental neurotoxicity induced by chemical mixtures.
Topics: Astrocytes; Benzhydryl Compounds; Biological Assay; Brain-Derived Neurotrophic Factor; Cell Differen | 2021 |
Whole genome microarray analysis of neural progenitor C17.2 cells during differentiation and validation of 30 neural mRNA biomarkers for estimation of developmental neurotoxicity.
Topics: Acrylamide; Animals; Biomarkers; Cell Differentiation; Cell Line; Cell Survival; Gene Expression Pro | 2017 |
Multifactorial non-cirrhotic hyperammonaemic encephalopathy.
Topics: Acetylcysteine; Aftercare; Anti-Bacterial Agents; Bacteremia; Carnitine; Female; Free Radical Scaven | 2018 |
Severe hyperammonaemic encephalopathy resulting from the overlap between hepatic and valproate encephalopathy.
Topics: Alcoholism; Brain Diseases; Epilepsy; Humans; Hyperammonemia; Hypertension, Portal; Male; Middle Age | 2018 |
Valproic Acid Induced Neurotoxicological Manifestations and its Mitigation by Melatonin in Rat Brain Synaptosomes.
Topics: Animals; Antioxidants; Brain; Glutathione; Lipid Peroxidation; Male; Melatonin; Membrane Potential, | 2018 |
Non-convulsive status epilepticus secondary to valproate-induced hyperammonaemic encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Neurotoxicity Syndromes; Status Epilepticus; Valproic Acid | 2020 |
QTc prolongation and valproate toxicity.
Topics: Anticonvulsants; Drug Overdose; Female; Humans; Medication Errors; Neurotoxicity Syndromes; Valproic | 2013 |
Valproate toxicity in a child.
Topics: Anticonvulsants; Drug Overdose; Female; Humans; Medication Errors; Neurotoxicity Syndromes; Valproic | 2013 |
Human Ntera2 cells as a predictive in vitro test system for developmental neurotoxicity.
Topics: Arsenites; Brain; Cell Differentiation; Cell Line; Cell Movement; High-Throughput Screening Assays; | 2014 |
Teaching neuroimages: reversible paradoxical lithium neurotoxicity.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Gadolinium; Humans; Lithium; Magnetic Resonance Imaging; | 2013 |
[Valproate-induced hyperammonemic encephalopathy in a neonate: treatment with carglumic acid].
Topics: Anticonvulsants; Glutamates; Humans; Hyperammonemia; Infant, Newborn; Male; Neurotoxicity Syndromes; | 2014 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; | 2014 |
Valproate-related hyperammonemic encephalopathy: report of 1 case.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Hyperammonemia; Neurotoxicity Syndromes; Valproi | 2014 |
Sodium valproate-related hyperammonaemic encephalopathy.
Topics: Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Male; Middle Aged; Neurotoxicity Syndromes; Valpr | 2014 |
Encephalopathy in an infant with infantile spasms: possible role of valproate toxicity.
Topics: Adrenocorticotropic Hormone; Ammonia; Anticonvulsants; Clonazepam; Drug Therapy, Combination; Female | 2014 |
MicroRNA profiling as tool for in vitro developmental neurotoxicity testing: the case of sodium valproate.
Topics: Animals; Cell Differentiation; Cell Line; Cell Survival; Cluster Analysis; Drug Discovery; Embryonic | 2014 |
Synthesis, physicochemical, and anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl analog.
Topics: Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug | 2014 |
[Woman in her 70s with rapidly increasing cognitive impairment].
Topics: Aged; Anti-Bacterial Agents; Anticonvulsants; Borrelia burgdorferi; Ceftriaxone; Cognition Disorders | 2014 |
Ammonium: the deadly toxin you don't want to miss when using mood stabilizers.
Topics: Adult; Aged, 80 and over; Ammonium Compounds; Female; Glutamic Acid; Humans; Hyperammonemia; Male; M | 2013 |
[Valproate can induce reversible encephalopathy].
Topics: Aged; Anticonvulsants; Brain Diseases; Epilepsy; Female; Humans; Magnetic Resonance Imaging; Neuroto | 2014 |
Acute renal and neurotoxicity in older lithium users: How can we manage and prevent these events in patients with late-life mood disorders?
Topics: Acute Kidney Injury; Aged; Bipolar Disorder; Humans; Lithium Compounds; Male; Neurotoxicity Syndrome | 2015 |
[Valproate can induce reversible encephalopathy].
Topics: Aged; Anticonvulsants; Brain Diseases; Epilepsy; Female; Humans; Magnetic Resonance Imaging; Neuroto | 2015 |
Lamotrigine might potentiate valproic acid-induced hyperammonemic encephalopathy.
Topics: Aged; Anticonvulsants; Drug Synergism; Female; Humans; Hyperammonemia; Lamotrigine; Neurotoxicity Sy | 2008 |
Hippocampal remodelling after MDMA neurotoxicity: a single case study.
Topics: Adolescent; Anticonvulsants; Body Temperature Regulation; Cognition Disorders; Electroencephalograph | 2009 |
Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Hyperam | 2008 |
Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient.
Topics: Atrophy; Bipolar Disorder; Brain; Female; Humans; Hyperammonemia; Middle Aged; Neurotoxicity Syndrom | 2009 |
Chronic dietary administration of valproic acid protects neurons of the rat nucleus basalis magnocellularis from ibotenic acid neurotoxicity.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Basal Nucleus of Meynert; Cerebral Cortex; Choline O-A | 2009 |
Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study.
Topics: Angelica archangelica; Animals; Anticonvulsants; Behavior, Animal; Cnidium; Coumarins; Dogs; Dose-Re | 2009 |
Observation of fetal brain in a rat valproate-induced autism model: a developmental neurotoxicity study.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain; Disease Models, Animal; Female; Fetus; Humans; M | 2009 |
mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach.
Topics: Animals; Animals, Newborn; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; | 2010 |
Valproic acid intoxication imitating brain death.
Topics: Anticonvulsants; Brain Death; Diagnosis, Differential; Humans; Male; Neurotoxicity Syndromes; Valpro | 2009 |
[Valproate-induced hyperammonemic encephalopathy].
Topics: Adult; Anticonvulsants; Humans; Hyperammonemia; Male; Neurotoxicity Syndromes; Valproic Acid | 2011 |
Bipolar disorder and valproate-induced hyperammonemic encephalopathy in an adolescent with diabetes.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Diabetes Mellitus, Type 1; Humans; Hyperammonemia; M | 2010 |
Lithium neurotoxicity at normal serum levels.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lithium Chloride; Male; Middle Aged; Neurotoxicity Syndr | 2010 |
[Valproate-induced hyperammononemic encefalopathy].
Topics: Anticonvulsants; Humans; Hyperammonemia; Male; Middle Aged; Neurotoxicity Syndromes; Valproic Acid | 2010 |
Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism.
Topics: Drug Synergism; Drug Therapy, Combination; Epilepsy; Female; Fructose; Humans; Hyperammonemia; Middl | 2011 |
A case of hyperammonaemic encephalopathy due to valproic acid.
Topics: Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Male; Middle Aged; Neurotoxicity Syndromes; Valpr | 2011 |
Valproate-induced hyperammonemia and seizures: perioperative concerns.
Topics: Anticonvulsants; Humans; Hyperammonemia; Infant; Magnetic Resonance Imaging; Male; Neurotoxicity Syn | 2011 |
Ammonemia in bipolar patients on maintenance treatment with valproic acid.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Female; Humans; Hyperammonemia; Male; Mood Diso | 2012 |
A severe valproate overdose with complete recovery in a newborn.
Topics: Anticonvulsants; Basal Ganglia; Female; Humans; Hyperammonemia; Infant, Newborn; Magnetic Resonance | 2012 |
Valproate toxicity in a child: two novel observations.
Topics: Anticonvulsants; Child, Preschool; Coma; Drug Overdose; Female; Half-Life; Hemofiltration; Humans; M | 2013 |
Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach.
Topics: Binding Sites; Cells, Cultured; Embryonic Stem Cells; Gene Expression Profiling; Gene Expression Reg | 2013 |
Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
Topics: Adolescent; Adult; Aged; Child, Preschool; China; Epilepsy; Female; Humans; Hyperammonemia; Male; Me | 2013 |
Ultrastructure of synaptic junctions in the cerebellar cortex in experimental valproate encephalopathy and after terminating chronic application of the antiepileptic.
Topics: Animals; Anticonvulsants; Cerebellar Cortex; Male; Neurotoxicity Syndromes; Rats; Rats, Wistar; Syna | 2002 |
Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.
Topics: Adult; Anticonvulsants; Atrophy; Brain; Electroencephalography; Excitatory Amino Acid Antagonists; H | 2003 |
Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures.
Topics: Animals; Animals, Newborn; Anticonvulsants; Astrocytes; Calcium; Calcium Signaling; Cell Membrane; C | 2003 |
Is the interaction between felbamate and valproate against seizures induced by 4-aminopyridine and pentylenetetrazole in mice beneficial?
Topics: 4-Aminopyridine; Analysis of Variance; Animals; Brain; Chromatography, Liquid; Disease Models, Anima | 2003 |
Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Coma; Diagnosis, Dual (Psychiatry); Electroencephalograph | 2003 |
Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Electroen | 2004 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Aggression; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorders; Child; Diagnosis, | 2004 |
Isobolographic and subthreshold analysis of interactions among felbamate and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice.
Topics: Animals; Anticonvulsants; Behavior, Animal; Clonazepam; Disease Models, Animal; Drug Interactions; D | 2004 |
[Valproate-induced hyperammonemic encephalopathy in a patient with Sjögren's syndrome].
Topics: Anticonvulsants; Epilepsy; Female; Humans; Hyperammonemia; Magnetic Resonance Imaging; Middle Aged; | 2004 |
Benefit of valproic acid in suppressing disease progression of ALS model mice.
Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Cell Count; Cell Death; Dicarboxylic Acids; Di | 2004 |
Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia.
Topics: Analysis of Variance; Animals; Animals, Newborn; CD11b Antigen; Cell Count; Cells, Cultured; Dopamin | 2005 |
Neurotoxicity associated with free valproic acid.
Topics: Antimanic Agents; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Psychotic Disorders; Valproic | 2005 |
Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study.
Topics: Adult; Age Distribution; Age Factors; Aged; Anticonvulsants; Antidepressive Agents; Benztropine; Coh | 2005 |
Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
Topics: Ammonia; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Female; Fructose; Huma | 2004 |
1-Methyl-1,2,3,4-tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model.
Topics: Animals; Anticonvulsants; Carbamazepine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Electroshoc | 2006 |
[Valproate-caused encephalopathy].
Topics: Aged; Anticonvulsants; Brain Diseases; Humans; Male; Mental Status Schedule; Neurotoxicity Syndromes | 2005 |
Ultrastructural study of cerebellar dentate nucleus astrocytes in chronic experimental model with valproate.
Topics: Animals; Anticonvulsants; Astrocytes; Blood-Brain Barrier; Cerebellar Nuclei; Male; Microscopy, Elec | 2005 |
Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
Topics: Adolescent; Aged; Anticonvulsants; Brain Diseases; Child, Preschool; Female; Humans; Hyperammonemia; | 2006 |
Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus.
Topics: Acute Disease; Electroencephalography; Female; Humans; Injections, Intravenous; Middle Aged; Neuroto | 2006 |
Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.
Topics: Animals; Anticonvulsants; Brain Chemistry; Clonazepam; Dioxolanes; Disease Models, Animal; Drug Inte | 2006 |
Is valproate encephalopathy under-recognised in older people? A case series.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Diagnosis, Differential; Electroencephalography; Epilepsy; | 2007 |
Valproate-induced developmental neurotoxicity is affected by maternal conditions including shipping stress and environmental change during early pregnancy.
Topics: Animal Husbandry; Animals; Anticonvulsants; Antimanic Agents; Brain; Female; Fetal Weight; Fetus; Ma | 2007 |
[Lithium intoxications at normal serum levels].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delirium; Dose-Response Relationship, Drug | 2008 |
[A valproate-induced encephalopathy without hyperammonemia].
Topics: Aged; Anticonvulsants; Female; Humans; Neurotoxicity Syndromes; Valproic Acid | 2007 |
Nitromethane encephalopathy MRI.
Topics: Adolescent; Anticonvulsants; Brain; Cerebellar Diseases; Cerebellum; Epilepsy, Tonic-Clonic; Humans; | 2008 |
A case of hyperammonemic encephalopathy after 11 years of valproate therapy.
Topics: Aged; Anticonvulsants; Bipolar Disorder; Delayed-Action Preparations; Drug Therapy, Combination; Hum | 2008 |
Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
Topics: Adolescent; Ammonia; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Female; Fru | 2000 |
Evaluating the tolerability of the newer mood stabilizers.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Central Nervous System Diseases; Cyclohexanecar | 2001 |
Stupor from lamotrigine toxicity.
Topics: Anticonvulsants; Coma; Drug Overdose; Epilepsy, Complex Partial; Female; Humans; Lamotrigine; Middle | 2001 |